









Markets
/
Stocks
/
nasdaq-nuvl
/

Nuvalent Inc

NUVL

76.670USD

-4.290-5.30%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

5.52BMarket Cap

LossP/E TTM



Nuvalent Inc

76.670

-4.290-5.30%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

195 / 506

Overall Ranking

319 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 14 analysts

Buy

Current Rating

117.700

Target Price

+45.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 218.56.

Overvalued

The company’s latest PE is -15.60, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 75.09M shares, decreasing 1.76% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.52M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -16.47, which is 16.21% below the recent high of -19.14 and -66.15% above the recent low of -27.36.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 195/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.71, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Nuvalent Inc is 113.00, with a high of 140.00 and a low of 100.00.

Score

Industry at a Glance

Previous score

8.71

Change

Support & Resistance

No Data

Analyst Rating

Based on 14 analysts

Buy

Current Rating

117.700

Target Price

+45.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Nuvalent Inc

NUVL

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.19, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 85.47 and the support level at 74.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.19

Change

-2.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.081

Neutral

RSI(14)

45.779

Neutral

STOCH(KDJ)(9,3,3)

32.885

Sell

ATR(14)

3.521

Low Volatility

CCI(14)

-71.889

Neutral

Williams %R

73.878

Sell

TRIX(12,20)

0.168

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

78.794

Sell

MA10

79.372

Sell

MA20

78.226

Sell

MA50

78.622

Sell

MA100

77.184

Sell

MA200

77.783

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 113.13%, representing a quarter-over-quarter decrease of 0.22%. The largest institutional shareholder is The Vanguard, holding a total of 4.52M shares, representing 6.77% of shares outstanding, with 1.06% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Deerfield Management Company, L.P.

17.99M

Fidelity Management & Research Company LLC

9.70M

+1.04%

Paradigm BioCapital Advisors LP

5.27M

-1.75%

The Vanguard Group, Inc.

Star Investors

4.43M

-1.34%

BlackRock Institutional Trust Company, N.A.

2.73M

-2.36%

Janus Henderson Investors

1.31M

+7785.15%

T. Rowe Price Associates, Inc.

Star Investors

1.42M

+12.26%

Shair (Matthew)

1.64M

+0.16%

Wellington Management Company, LLP

1.44M

+12.28%

State Street Global Advisors (US)

1.43M

-3.96%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.94, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.